Home » Case Studies » Value Access and Pricing » Maximizing P&MA Opportuni…

Maximizing P&MA Opportunity

CBPartners identified the risks & opportunities for PRODUCT X’s P&MA strategy in China in the context of the current & future market access environment.


Review and refresh the CHN access strategy for PRODUCT X by testing current and future cardiovascular disease (CVD) products with payers and key opinion leaders (KOLs) to identify the appropriate target population and likely pricing impact of National Reimbursement Drug List (NRDL) inclusion.



Assess the current CVD landscape in CHN via targeted secondary research, conduct primary research with payers and KOLs to review perceptions of current and future CVD products’ and understand the access and pricing potential of PRODUCT X at the national level.


  • Secondary research findings
  • Detailed reports to reflect market dynamics and payer / KOL perceptions on PRODUCT X
  • Key recommendations to inform the PRODUCT X strategy to optimize its future access in CHN

Illustrative Outputs


CBPartners developed manufacturer strategies to maximize pricing and access opportunity in CHN, both during NRDL submission and in the future